Beta Bionics price target raised to $31 from $26 at Stifel

Stifel analyst Jonathan Block raised the firm’s price target on Beta Bionics (BBNX) to $31 from $26 and keeps a Buy rating on the shares following “a solid quarter,” with revenue and new adds upside and management “again” raising 2025 guidance. The quarter/guidance “appeared virtually flawless” until management disclosed the recent issuance in June of a Form 483 and while “some may focus on the 483 news,” the firm now knows that the high reporting of events in recent months was due to the new reporting classification, the analyst tells investors.